Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lindsey Roeker"'
Autor:
Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han, Xiaowei Zhang, Lindsey Roeker, Nicola Wallis, Jennifer C. Stern, Eric Hedrick, Jane Huang, Jeff P. Sharman
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 135-144 (2023)
Abstract Ibrutinib, a Bruton's tyrosine kinase inhibitor, is often used as first‐line (1L) treatment of chronic lymphocytic leukaemia (CLL); however, it is associated with an increased risk for cardiovascular adverse events (CVAEs). This real‐wor
Externí odkaz:
https://doaj.org/article/6e2bc983c365456688227cc361fb4cc9
Autor:
Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Lindsey Roeker, Benoit Tessoulin, Alexey Danilov, Alvaro J. Alencar, Nirav N. Shah, Herve Ghesquieres, Steven Le Gouill, Wojciech Jurczak, Anthony R. Mato, Vishalkumar Patel, Yingying Guo-Avrutin, James M. Pauff, Maciej Kazmierczak
Publikováno v:
HemaSphere, Vol 7, p e216785f (2023)
Externí odkaz:
https://doaj.org/article/88e61ece0ef54dbf9c6551b4c45ba994
Autor:
Joanna Rhodes, Mazyar Shadman, Nicole Lamanna, Beenish S. Manzoor, Catherine Coombs, Nilanjan Ghosh, Hande H. Tuncer, Dozie Emechebe, Jennifer R. Brown, Hasan Alhasani, Lori Leslie, Lindsey Roeker, Chaitra Ujjani, Barbara Eichhorst, Isabelle Fleury, Alan Skarbnik, Brian T. Hill, Frederick Lansigan, Paul M. Barr, Matthew Davids, Christopher Fox, Yun Choi, Christopher E. Jensen, Anna Schuh, Kaitlin Kennard, Dureshahwar Jawaid, Irina Pivneva, Talissa Watson, Toby Eyre
Publikováno v:
HemaSphere, Vol 7, p e96103aa (2023)
Externí odkaz:
https://doaj.org/article/ec2367ab9e2243108286397129a56d1d
Autor:
Jonathon Cohen, Lindsey Roeker, Chan Cheah, Toby Eyre, Krish Patel, Jennifer Woyach, John Seymour, Michael Wang, Yucai Wang, Angely Loubert, Nalin Payakachat, Lisa Hess, Paolo Abada, Anthony R. Mato, Paolo Ghia
Publikováno v:
HemaSphere, Vol 7, p e34270c5 (2023)
Externí odkaz:
https://doaj.org/article/141afaa557b54ed89782ff349bd546ff
Autor:
Matthew Karr, Lindsey Roeker
Publikováno v:
Cancers, Vol 15, Iss 4, p 1018 (2023)
Over the last 10 years, the traditional treatment paradigms for CLL have been upended as the use of traditional chemoimmunotherapy regimens has declined in favor of novel targeted therapies. Targeted therapies have become the new standard of care in
Externí odkaz:
https://doaj.org/article/2bd9766acd2f4397bdd5014625be8106
Autor:
Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Allison Winter, Nicole Lamanna, Constantine S. Tam, Ryan Jacobs, Frederick Lansigan, Paul M. Barr, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Alison R. Sehgal, Stephen J. Schuster, Nirav N. Shah, Chaitra S. Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, the GIMEMA, European Research Initiative (ERIC) on CLL, US study group
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8468-8479 (2020)
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patie
Externí odkaz:
https://doaj.org/article/51d4f3af2edb4e18930e0b7ba14d8eff